Experimental HIV Drugs
Experimental HIV Drugs
Coverage of the XIX International AIDS Conference
- Details
- Category: HIV Treatment
- Published on Friday, 27 July 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the XIX International AIDS Conference (AIDS 2012), July 22-27 in Washington, DC.
Conference highlights include experimental antiretroviral drugs, treatment as prevention and PrEP, scaling up HIV treatment and prevention in resource-limited countries, human rights and concerns of heavily impacted populations, AIDS policy and advocacy, HIV/HBV and HIV/HCV coinfection, and the search for a cure for HIV.
HIVandHepatitis.com AIDS 2012 conference section
7/27/12
Advocates Release Updated Report on Pipeline Drugs for HIV, Hepatitis C, and TB
- Details
- Category: Experimental HIV Drugs
- Published on Saturday, 21 July 2012 00:00
- Written by Press Release
Drugs are HIV are more effective and plentiful than ever, but in many cases they are not making it into the hands of people who need them, according the 2012 Pipeline Report, released July 21 by HIV i-Base and the Treatment Action Group (TAG). Development of new direct-acting agents for hepatitis C, however, is occurring at a rapid pace.
Gilead Submits Applications for FDA Approval of Elvitegravir and Cobicistat
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 29 June 2012 00:00
- Written by Liz Highleyman
On June 27 Gilead Sciences announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of its new integrase inhibitor, elvitegravir, for use in combination antiretroviral therapy for treatment-experienced adults with HIV. The following day the company also requested approval of its novel boosting agent cobicistat.
Dolutegravir Combo Beats Atripla in Phase 3 Study of Previously Untreated HIV Patients
- Details
- Category: HIV Treatment
- Published on Friday, 13 July 2012 00:00
- Written by Press Release
ViiV Healthcare and Japan's Shionogi announced this week that a combination antiretroviral regimen containing the experimental integrase inhibitor dolutegravir suppressed HIV viral load as well as the popular Atripla (efavirenz/tenofovir/emtricitabine) coformulation in treatment-naive individuals, but with fewer side effects.
Quad Pill Matches Atripla and Atazanavir for First-line HIV Treatment
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 29 June 2012 00:00
- Written by Liz Highleyman
Gilead's investigational Quad pill, a 4-in-1 coformulation containing the second-generation integrase inhibitor elvitegravir and a new boosting agent, performed as well as either the 3-in-1 Atripla coformulation or the popular protease inhibitor atazanavir (Reyataz) in Phase 3 studies, researchers reported in the June 30, 2012, issue of The Lancet.
More Articles...
- FDA Advisors Favor Approval of 4-in-1 Elvitegravir Quad Pill for HIV
- Novel HIV Integrase Inhibitor Dolutegravir Matches Raltegravir in Phase 3 Study
- Coverage of the 2012 Conference on Retroviruses and Opportunistic Infections
- CROI 2012: 4-in-1 Elvitegravir Quad Pill Matches Efavirenz and Atazanavir Combos
Web Design and Development by